<scp>IGF</scp>2<scp>BP</scp>2 promotes colorectal cancer cell proliferation and survival through interfering with <i><scp>RAF</scp>‐1</i> degradation by miR‐195

Song, Yanshuang; Song, Wei; Xu, Xiaogang; Zhao, Xinyi; Yang, Liu

doi:10.1002/1873-3468.12205

Cited by 99 publications

(82 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on the GO and KEGG analyses of more than 60 esophageal adenocarcinoma patients, it has been reported that IGF2BP2 is significantly associated with proliferation and growth [10]. In addition, a recent study reported that the knockdown of IGF2BP2 expression in colorectal cancer cells suppressed cell growth [31]. Our results also showed that the knockdown of IGF2BP2 expression in AML cell lines obviously repressed cell growth.…”

Section: Discussionsupporting

confidence: 66%

IGF2BP2 Overexpression Indicates Poor Survival in Patients with Acute Myelocytic Leukemia

Liang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: IGF2BP2 has been reported to serve as an oncogene in various solid cancers. However, the role of IGF2BP2 in acute myelocytic leukemia (AML) is still unknown. Methods: Public databases Gene Omnibus was used to evaluate the expression of IGF2BP2 in AML patients and healthy controls. In addition, primary cells from these two populations were prepared by Ficoll density centrifugation. Rt-qPCR and western blot were used to detect IGF2BP2 expression in the primary cells from these two populations. Meta-analysis was performed to evaluate the association of IGF2BP2 and prognosis. Lentivirus-based shRNAs were used to knock down IGF2BP2 in AML cell lines KG-1a and Kasumi. Results: We searched the public database Gene Omnibus and analyzed IGF2BP2 expression in both AML and healthy populations. The results showed that IGF2BP2 was overexpressed in AML patients. To verify this phenomenon in fresh human samples, we compared the expression of IGF2BP2 in primary cells from 10 AML patients and 10 healthy controls and found that the expression of IGF2BP2 was upregulated in AML primary cells. More importantly, we observed that IGF2BP2 expression was negatively correlated with the CEBPA mutation status, which is an indicator of good prognosis (RR=0.648, p=0.0001). In addition, IGF2BP2 expression was positively associated with poor prognostic factors, such as the FLT3-ITD mutation (RR=1.198, p=0.0009) and IDH1 mutation (RR=1.354, p=0.0003), as well as intermediate and poor cytogenetic risk (RR=1.214, p=0.0026). To evaluate the prognostic value of IGF2BP2 in AML, we further performed a meta-analysis of 8 studies consisting of 1731 patients and found that IGF2BP2 overexpression was correlated with worse overall survival in AML patients [HR=1.31(1.16-1.49); p = 0.00]. Furthermore, we performed Gene Omnibus and Gene Set Enrichment analyses and found that the genes regulated by IGF2BP2 were mainly enriched in cell proliferation. IGF2BP2 knockdown by 4 different shRNA vectors significantly inhibited the growth of two AML cell lines, KG-1a and Kasumi. Conclusion: Thus, IGF2BP2 may serve as a biomarker to predict the prognosis of AML and as a potential target in AML.

show abstract

Section: Discussionsupporting

confidence: 66%

IGF2BP2 Overexpression Indicates Poor Survival in Patients with Acute Myelocytic Leukemia

Liang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…IGF2BP2-AS1 is a lncRNA located in the IGF2BP2 antisense strand. IGF2BP2 promotes many cancer types [40–42], and IGF2BP2-AS1 might regulate IGF2BP expression, thus suppressing LUSC development and progression. DGCR5 is a DiGeorge syndrome-related gene [43], and its role in cancers is currently uncertain.…”

Section: Discussionmentioning

confidence: 99%

LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma

2016

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have been implicated in pathogenesis of various cancers, including lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD). We used cBioPortal to analyze lncRNA alteration frequencies and their ability to predict overall survival (OS) using 504 LUSC and 522 LUAD samples from The Cancer Genome Atlas (TCGA) database. In LUSC, 624 lncRNAs had alteration rates > 1% and 64 > 10%. In LUAD 625 lncRNAs had alteration rates > 1% and 36 > 10%. Among those, 620 lncRNAs had alteration frequencies > 1% in both LUSC and LUAD, while 22 were LUSC-specific and 23 were LUAD-specific. Twenty lncRNAs had alteration frequencies > 10% in both LUSC and LUAD, while 44 were LUSC-specific and 16 were LUAD specific. Genome ontology and pathway analyses produced similar results for LUSC and LUAD. Two lncRNAs (IGF2BP2-AS1 and DGCR5) correlated with better OS in LUSC, and three (MIR31HG, CDKN2A-AS1 and LINC01600) predicted poor OS in LUAD. Chip-seq and luciferase reporter assays identified potential IGF2BP2-AS1, DGCR5 and LINC01600 promoters and enhancers. This study presented lncRNA landscapes and revealed differentially expressed, highly altered lncRNAs in LUSC and LUAD. LncRNAs that act as oncogenes and lncRNA-regulating transcription factors provide novel targets for anti-lung cancer therapeutics.

show abstract

“…Similarly, IGF2BP2 can inhibit the translation of the mitochondrial transport protein, uncoupling protein‐1 (UCP1), a protein which has was shown to bring about autophagy and cell death in a breast cancer model . Elevated levels of IGF2BP2 are also linked to increased rates of metastasis and poor survival in other cancers, including oesophageal and colorectal carcinomas .…”

Section: Identification Of Pro‐oncogenic Factors In 3q26‐29mentioning

confidence: 99%

3q26‐29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes

Davidson

Shanks

2017

The FEBS Journal

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is significantly underrepresented in worldwide cancer research, yet survival rates for the disease have remained static for over 50 years. Distant metastasis is often present at the time of diagnosis, and is the primary cause of death in cancer patients. In the absence of routine effective targeted therapies, the standard of care treatment remains chemoradiation in combination with (often disfiguring) surgery. A defining characteristic of HNSCC is the amplification of a region of chromosome 3 (3q26‐29), which is consistently associated with poorer patient outcome. This review provides an overview of the role the 3q26‐29 region plays in HNSCC, in terms of both known and as yet undiscovered processes, which may have potential clinical relevance.

show abstract

IGF2BP2 promotes colorectal cancer cell proliferation and survival through interfering with RAF‐1 degradation by miR‐195

Cited by 99 publications

References 30 publications

IGF2BP2 Overexpression Indicates Poor Survival in Patients with Acute Myelocytic Leukemia

IGF2BP2 Overexpression Indicates Poor Survival in Patients with Acute Myelocytic Leukemia

LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma

3q26‐29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes

Contact Info

Product

Resources

About